HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
Huagongshe Open Program:[email protected]AI access: llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.7.8
  1. Home
  2. /Compound

1,2,3,7,8-Pentachlorodibenzo-p-dioxin

HCID 38439
NotesReactions
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
40321-76-4
Standard SMILES
Clc1cc2c(cc1Cl)Oc1c(cc(Cl)c(Cl)c1Cl)O2
InChIKey
FSPZPQQWDODWAU-UHFFFAOYSA-N
Molecular formula
C12H3Cl5O2
Average molar mass
356.4 g/mol
Monoisotopic mass
353.857568

Overview

1,2,3,7,8-Pentachlorodibenzodioxin is a polychlorinated dibenzodioxine.

Names & identifiers

Preferred name
1,2,3,7,8-Pentachlorodibenzo-p-dioxin
IUPAC
1,2,3,7,8-pentachlorodibenzo-p-dioxin
English name
1,2,3,7,8-PENTACHLORODIBENZO-P-DIOXIN
Molecular formula
C12H3Cl5O2
Molecular weight
356.42

Names & synonyms

1,2,3,7,8-PENTACHLORODIBENZO-P-DIOXIN40321-76-41,2,3,7,8-Pentachlorodibenzodioxin1,2,3,7,8-PeCDDPCDD 54Dibenzo-p-dioxin, 1,2,3,7,8-pentachloro-2NE6H0QPCHDTXSID70520781,2,3,7,8-Pentachlorooxanthrene1,2,3,7,8-Pentachlorodibenzo(b,e)(1,4)dioxin1,2,3,7,8-Pentachlorodibenzo[b,e][1,4]dioxinDibenzo(b,e)(1,4)dioxin, 1,2,3,7,8-pentachloro-
Show more names
1,2,3,7,8-PCDD1,2,3,7,8-PNCDDPentachlorobenzo-p-dioxin, 1,2,3,7,8-1,2,3,7,8-pentachloro-dibenzo-p-dioxi2,3,4,7,8-Pentachlorodibenzo[1,4]dioxin1,2,3,7,8-PENTACHLORODIBENZO-PARA-DIOXIN
PeCDDRefChem:71372DTXCID2030645694-814-9CHEMBL137220BRN 16268441,2,3,7,8-Pentachlorodibenzo-p-dioxin (>85%)UNII-2NE6H0QPCH

Database identifiers

CAS
40321-76-4

Properties

Computed structural properties

XLogP
6.6
Topological polar surface area
18.5 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
2
Rotatable bonds
0
Heavy atoms
19
Formal charge
0
Complexity
344

Experimental & physicochemical properties

SpringerMaterials PropertiesBoiling point
LogP6.64
Endocrine DisruptorsPotential endocrine disrupting compound
Collision Cross Section165.2 Ų [M]+ [CCS Type: TIMS, Method: calibration with PAHs]

Physicochemical properties

Melting point
206 °C · 206°C (estimate)
Boiling point
442.63 °C · 442.63°C (rough estimate)
Density
1.78 · 1.7800 (estimate)
refractive index
1.661 · 1.6610 (estimate)
solubility
n-nonane: Soluble
Henry's Law Constant
5.2 · 5.2×10-5 mol/(m3Pa) at 25℃, Paasivirta et al. (1999)
EWG's Food Scores
3 · 3
FDA UNII
2 NE6H0QPCH · 2NE6H0QPCH

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]

P264, P270, P273, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 39 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 2 items

Hazard Traits - Bioaccumulation; Carcinogenicity; Dermatotoxicity; Endocrine Toxicity; Environmental Persistence; Environmental tox; Hematotoxicity; Hepatotoxicity and Digestive System Toxicity; Reproductive Toxicity; Respiratory Toxicity

Regulation (EC) No 178/2002 (amended)

Hazard Classes and CategoriesAcute Tox. 1 (100%)

Safety & protection

Minimum Risk LevelAcute Oral: 0.0002 ug/kg/day (L134) Intermediate Oral: 0.00002 ug/kg/day (L134) Chronic Oral: 0.000001 ug/kg/day (L134)
Protective Action Criteria (PAC) · 3 items

0.00013 [mg/m3]

0.0014 [mg/m3]

0.0085 [mg/m3]

Toxicology

TreatmentTreatment of CDD exposure may include washing the area of contact, GI decontamination, administering an IV, or forced alkaline diuresis. (L346)

Chemistry & industry

Pharmacology

Metabolism/Metabolites · 1 item

CDDs are absorbed through oral, inhalation, and dermal routes of exposure. CDDs are carried in the plasma by serum lipids and lipoproteins, distributing mainly to the liver and adipose tissue. CDDs are very slowly metabolized by the microsomal monooxygenase system to polar metabolites that can undergo conjugation with glucuronic acid and glutathione. They may increase the rate of their own metabolism by inducing both phase I and phase II enzymes. The major routes of excretion of CDDs are the bile and the faeces, though smaller amounts are excreted in the urine and via lactation. (L177)

Uses & manufacturing

Uses · 1 item

Dioxins occur as by-products from the manufacture of organochlorides, the bleaching of paper, chlorination by waste and drinking water treatment plants, municipal solid waste and industrial incinerators, and natural sources such as volcanoes and forest fires. (L177, L178)

Applications

UsesA toxic polychlorinated dibenzo-p-dioxin detected in domestic meat and poultry.

Upstream & downstream products

Upstream raw materials

2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN1,2,3,4,7,8-HEXACHLORODIBENZO-P-DIOXIN1,2,3,6,7,8-HEXACHLORODIBENZO-P-DIOXIN2,4,5-Trichlorophenol

Additional notes

Related reactions

0 records
New reaction record

No reaction records under the current filter.

Compound notes

Loading…

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
PubChem CID
38439
DTXSID
DTXSID7052078
ChEMBL
CHEMBL137220
ChEBI
CHEBI:81501
UNII
2NE6H0QPCH
EC Number
694-814-9
Nikkaji
J34.849J
EPA Substance Registry System
1 · 1,2,3,7,8-Pentachlorodibenzo-p-dioxin (40321-76-4)
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
300 · H300-H413
Precautionary statements
264 · P264-P270-P301+P310-P321-P330-P405-P501
RIDADR
2811 · 2811
HazardClass
6.1 · 6.1(a)
PackingGroup
I
Toxicity
50 orl-rat: · LD50 orl-rat: 206 mg/kg ARTODN 66,471,92
Health Effects · 1 item

Exposure to large amounts of CDDs causes chloracne, a severe skin disease with acne-like lesions that occur mainly on the face and upper body. CDDs may also cause liver damage and induce long-term alterations in glucose metabolism and subtle changes in hormonal levels. In addition, studies have shown that CDDs may disrupt the endocrine system and weaken the immune system, as well as cause reproductive damage and birth defects, central and peripheral nervous system pathology, thyroid disorders, endometriosis, and diabetes. (L177, L178)

Exposure RoutesOral (L177) ; inhalation(L177) ; dermal (L177)
Toxicity Summary · 1 item

CDDs cause their toxic effects by binding to the aryl hydrocarbon receptor and subsequently altering the transcription of certain genes. The affinity for the Ah receptor depends on the structure of the specific CDD. The change in gene expression may result from the direct interaction of the Ah receptor and its heterodimer-forming partner, the aryl hydrocarbon receptor nuclear translocator, with gene regulatory elements or the initiation of a phosphorylation/dephosphorylation cascade that subsequently activates other transcription factors. The affected genes include several oncogenes, growth factors, receptors, hormones, and drug-metabolizing enzymes. The change in transcription/translation of these genes is believed to be the cause of most of the toxic effects of CDDs. (L177)

Signs and SymptomsIn addition to chloracne, CDD exposure causes skin rashes, discoloration, and excessive body hair. (L177)
Carcinogen Classification3, not classifiable as to its carcinogenicity to humans. (L135)
RAIS Toxicity Values · 6 items

38

WHO/TEF

4e-08

WHO/TEF

7e-10

WHO/TEF

Safety data

ridadr
2811
Toxicity
LD50 orl-rat: 206 mg/kg ARTODN 66,471,92
Signal word
Danger
Symbol(GHS)
GHS06
hazard_class
6.1(a)
packing_group
I
Hazard statements
H300-H413
Precautionary statements
P264-P270-P301+P310-P321-P330-P405-P501

DefinitionChEBI: 1,2,3,7,8-Pentachlorodibenzodioxin is a polychlorinated dibenzodioxine.